CA1136548A - Sustained release pharmaceutical formulation - Google Patents
Sustained release pharmaceutical formulationInfo
- Publication number
- CA1136548A CA1136548A CA000343711A CA343711A CA1136548A CA 1136548 A CA1136548 A CA 1136548A CA 000343711 A CA000343711 A CA 000343711A CA 343711 A CA343711 A CA 343711A CA 1136548 A CA1136548 A CA 1136548A
- Authority
- CA
- Canada
- Prior art keywords
- indoprofen
- cellulose ether
- tablets
- cellulose
- microencapsulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 7
- 238000013268 sustained release Methods 0.000 title claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 claims abstract description 72
- 229960004187 indoprofen Drugs 0.000 claims abstract description 72
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 48
- 239000011859 microparticle Substances 0.000 claims abstract description 17
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 13
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 13
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 13
- 239000011253 protective coating Substances 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 41
- 239000003826 tablet Substances 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 17
- 239000006185 dispersion Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 238000013019 agitation Methods 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 10
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 229920005549 butyl rubber Polymers 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- UCEXMJMSILZCHZ-UHFFFAOYSA-N 2-[(4-butoxybenzoyl)amino]acetic acid Chemical group CCCCOC1=CC=C(C(=O)NCC(O)=O)C=C1 UCEXMJMSILZCHZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001033 ether group Chemical group 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical group C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 3
- 229940065347 propoxyphene hydrochloride Drugs 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000007939 sustained release tablet Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- QWHDIFKBCCVIFM-XTEKXEGTSA-J dicalcium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol phosphonato phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO QWHDIFKBCCVIFM-XTEKXEGTSA-J 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- -1 ethoxyl Chemical group 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US697179A | 1979-01-25 | 1979-01-25 | |
| US6,971 | 1979-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1136548A true CA1136548A (en) | 1982-11-30 |
Family
ID=21723530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000343711A Expired CA1136548A (en) | 1979-01-25 | 1980-01-15 | Sustained release pharmaceutical formulation |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS55100314A (OSRAM) |
| CA (1) | CA1136548A (OSRAM) |
| DE (1) | DE3001797A1 (OSRAM) |
| FR (1) | FR2447192A1 (OSRAM) |
| GB (1) | GB2041222B (OSRAM) |
| IT (1) | IT1129713B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57209223A (en) * | 1981-06-19 | 1982-12-22 | Tanabe Seiyaku Co Ltd | Microcapsule for intracranial anti hypotension and its production |
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US5232769A (en) * | 1989-08-01 | 1993-08-03 | Kanebo, Ltd. | Microcapsule, treating liquids containing the same, and textile structure having microcapsules adhering thereto |
| ATE114472T1 (de) * | 1989-09-21 | 1994-12-15 | American Cyanamid Co | System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe. |
| EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
| IE64128B1 (en) * | 1990-02-26 | 1995-07-12 | Byrne Rynne Holdings Ltd | A pharmaceutical composition |
| US5262173A (en) * | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155590A (en) * | 1962-08-02 | 1964-11-03 | Ncr Co | Encapsulation process and its product |
| US3557279A (en) * | 1969-06-12 | 1971-01-19 | Merck & Co Inc | Microencapsulation form of an anti-inflammatory drug |
| JPS5432614A (en) * | 1977-08-11 | 1979-03-10 | Tanabe Seiyaku Co Ltd | Preparation of microcapsules containing pharmaceuticals |
-
1979
- 1979-12-20 FR FR7931253A patent/FR2447192A1/fr active Granted
-
1980
- 1980-01-15 CA CA000343711A patent/CA1136548A/en not_active Expired
- 1980-01-18 DE DE19803001797 patent/DE3001797A1/de not_active Withdrawn
- 1980-01-24 GB GB8002402A patent/GB2041222B/en not_active Expired
- 1980-01-24 JP JP640080A patent/JPS55100314A/ja active Pending
- 1980-01-24 IT IT19430/80A patent/IT1129713B/it active
Also Published As
| Publication number | Publication date |
|---|---|
| GB2041222A (en) | 1980-09-10 |
| IT1129713B (it) | 1986-06-11 |
| GB2041222B (en) | 1983-05-11 |
| DE3001797A1 (de) | 1980-08-07 |
| FR2447192B1 (OSRAM) | 1983-08-19 |
| JPS55100314A (en) | 1980-07-31 |
| IT8019430A0 (it) | 1980-01-24 |
| FR2447192A1 (fr) | 1980-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4316884A (en) | Sustained release pharmaceutical formulation | |
| CA1297017C (en) | Controlled release pharmaceutical composition | |
| EP3131533B1 (en) | Oral dosage form of ketamine | |
| DK174992B1 (da) | Farmaceutisk præparat med langsom frigivelse samt anvendelse af visse additiver i sådanne til opnåelse af langsom frigivelse | |
| JP2778030B2 (ja) | 経口投与用液体製剤 | |
| EP0076515B1 (en) | Rapidly releasable microcapsules and method for the preparation thereof | |
| EP1110553B1 (en) | Sustained release oral preparations of fasudil hydrochloride | |
| EP2590630B1 (en) | Oral dosage form of deferasirox | |
| US4867987A (en) | Pharmaceutical product for the sustained release of ibuprofen | |
| JPH0780788B2 (ja) | 徐放性医薬組成物 | |
| KR20090119993A (ko) | 구강내 붕괴정 | |
| KR20010082251A (ko) | 서방성 입자 | |
| EP1210066A1 (en) | Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants | |
| JPH0753365A (ja) | γ−ヒドロキシ酪酸塩による制御放出能をもつ薬化学組成物 | |
| EP0231826A2 (en) | Theophylline sustained release tablet | |
| JPS6345219A (ja) | 持続性経皮吸収製剤 | |
| HRP20010198A2 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
| JPS6351735B2 (OSRAM) | ||
| AU698784B2 (en) | Alkalinizing potassium salt controlled release preparations | |
| WO2007112574A1 (en) | Extended release composition of venlafaxine | |
| GB2041222A (en) | Sustained release indoprofen formulation | |
| WO2000020017A2 (en) | Controlled-release garlic formulations | |
| CN1091600C (zh) | 盐酸地尔硫䓬控释片的制备方法 | |
| CN100522169C (zh) | 盐酸雷诺嗪缓释制剂及其制备方法 | |
| FI95776C (fi) | Menetelmä tehoainetta alhaisen annoksen kontrolloidusti vapauttavien aspiriinitablettien valmistamiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |